170 related articles for article (PubMed ID: 15840485)
1. Catecholaminergic polymorphic ventricular tachycardia.
Francis J; Sankar V; Nair VK; Priori SG
Heart Rhythm; 2005 May; 2(5):550-4. PubMed ID: 15840485
[TBL] [Abstract][Full Text] [Related]
2. Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.
Garabedian L; Verryckt A; Panzer J; De Wolf D
Acta Paediatr; 2008 Jan; 97(1):127-9. PubMed ID: 18052993
[TBL] [Abstract][Full Text] [Related]
3. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
4. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
5. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
6. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
7. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Priori SG
Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
[TBL] [Abstract][Full Text] [Related]
8. A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia.
Bosch C; Campuzano O; Sarquella-Brugada G; Cesar S; Perez-Serra A; Coll M; Mademont I; Mates J; Del Olmo B; Iglesias A; Brugada J; Petersen V; Brugada R
Forensic Sci Int; 2017 Jan; 270():173-177. PubMed ID: 27988446
[TBL] [Abstract][Full Text] [Related]
9. Catecholaminergic Polymorphic Ventricular Tachycardia.
Kim CW; Aronow WS; Dutta T; Frenkel D; Frishman WH
Cardiol Rev; 2020; 28(6):325-331. PubMed ID: 31934898
[TBL] [Abstract][Full Text] [Related]
10. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
Katz G; Arad M; Eldar M
Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
[TBL] [Abstract][Full Text] [Related]
11. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Colombi B; Raytcheva-Buono EV; Bloise R; Priori SG
Herz; 2007 May; 32(3):212-7. PubMed ID: 17497254
[TBL] [Abstract][Full Text] [Related]
12. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
[TBL] [Abstract][Full Text] [Related]
13. A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations.
de la Fuente S; Van Langen IM; Postma AV; Bikker H; Meijer A
Pacing Clin Electrophysiol; 2008 Jul; 31(7):916-9. PubMed ID: 18684293
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
[TBL] [Abstract][Full Text] [Related]
15. Genetic characterization of familial CPVT after 30 years.
Beery TA; Shah MJ; Benson DW
Biol Res Nurs; 2009 Jul; 11(1):66-72. PubMed ID: 19398417
[TBL] [Abstract][Full Text] [Related]
16. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms.
Laitinen PJ; Swan H; Kontula K
Eur J Hum Genet; 2003 Nov; 11(11):888-91. PubMed ID: 14571276
[TBL] [Abstract][Full Text] [Related]
18. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.
Terentyev D; Nori A; Santoro M; Viatchenko-Karpinski S; Kubalova Z; Gyorke I; Terentyeva R; Vedamoorthyrao S; Blom NA; Valle G; Napolitano C; Williams SC; Volpe P; Priori SG; Gyorke S
Circ Res; 2006 May; 98(9):1151-8. PubMed ID: 16601229
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: A Translational Perspective for the Clinician-Scientist.
Kallas D; Lamba A; Roston TM; Arslanova A; Franciosi S; Tibbits GF; Sanatani S
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502196
[TBL] [Abstract][Full Text] [Related]
20. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Cerrone M; Noujaim SF; Tolkacheva EG; Talkachou A; O'Connell R; Berenfeld O; Anumonwo J; Pandit SV; Vikstrom K; Napolitano C; Priori SG; Jalife J
Circ Res; 2007 Nov; 101(10):1039-48. PubMed ID: 17872467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
